Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Boundless Bio Inc (BOLD)

Boundless Bio Inc (BOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,757
  • Shares Outstanding, K 22,300
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,430 K
  • EBIT $ -69 M
  • EBITDA $ -68 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.70
  • Low Estimate -0.78
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.33 +11.16%
on 11/22/24
3.54 -26.84%
on 12/11/24
-0.12 (-4.43%)
since 11/20/24
3-Month
2.33 +11.16%
on 11/22/24
4.57 -43.26%
on 09/23/24
-1.81 (-41.14%)
since 09/20/24

Most Recent Stories

More News
Boundless Bio Updates Clinical Trial Progress, Leadership Changes, and Future Development Plans

Boundless Bio announces leadership changes, halts BBI-825 trial, advances third ecDTx program, and extends operational runway to 2027.Quiver AI SummaryBoundless Bio has announced it will not advance BBI-825...

BOLD : 2.59 (+2.78%)
Boundless Bio Announces Pipeline and Leadership Updates

BOLD : 2.59 (+2.78%)
Boundless Bio to Participate in the Piper Sandler Healthcare Conference

BOLD : 2.59 (+2.78%)
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

BOLD : 2.59 (+2.78%)
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

BOLD : 2.59 (+2.78%)
Boundless Bio Announces Departure of Chief Financial Officer

BOLD : 2.59 (+2.78%)
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

/CNW/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...

BIOV.CN : 0.0650 (+8.33%)
BVAXF : 0.0475 (+2.15%)
MRNA : 39.39 (-0.43%)
BOLD : 2.59 (+2.78%)
IBRX : 2.62 (-1.87%)
MGNX : 3.18 (unch)
Promising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising Diagnoses

USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society...

BRX : 27.40 (+1.14%)
BIOV.CN : 0.0650 (+8.33%)
BVAXF : 0.0475 (+2.15%)
MRNA : 39.39 (-0.43%)
BOLD : 2.59 (+2.78%)
IBRX : 2.62 (-1.87%)
MGNX : 3.18 (unch)

Business Summary

Boundless Bio Inc. is a clinical stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers. Boundless Bio Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 3.19
2nd Resistance Point 3.02
1st Resistance Point 2.81
Last Price 2.59
1st Support Level 2.43
2nd Support Level 2.26
3rd Support Level 2.05

See More

52-Week High 15.24
Fibonacci 61.8% 10.31
Fibonacci 50% 8.78
Fibonacci 38.2% 7.26
Last Price 2.59
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar